Navigation Links
Dr. Laura T. Lawrence, Board Certified Reproductive Endocrinologist, Joins Dallas-Fort Worth Fertility Associates
Date:8/5/2014

syndrome in her teens. This experience led her to pursue nationally recognized research into PCOS. Her research investigating glucose intolerance and its corresponding effect on reproduction was supported by several prestigious grants and selected for presentation at multiple national meetings. She was also honored with a Society of Gynecologic Investigation President’s Presenter award.

“Her experience with and research into PCOS, in addition to her special interest in areas like low egg reserve, repeated miscarriages and male factor infertility, will provide our patients with an empathetic and informed approach that they will appreciate,” adds Dr. Chantilis.

For the past five years, Dr. Lawrence has been in practice in the Fort Worth area, serving as the Medical Director of the Harris Methodist ARTS (IVF) Lab. She has been recognized repeatedly with the distinction of Top Doctors from Fort Worth magazine. Dr. Lawrence is looking forward to continuing her tradition of top-notch patient care as part of the DFW Fertility Associates team.

“I hope to use my personal experience and medical expertise to continue to help couples who are struggling with infertility to create their families. I understand their issues and empathize with their obstacles, and it’s an honor to help them.”

About Dallas-Fort Worth Fertility Associates
Dallas-Fort Worth Fertility Associates is a
'/>"/>

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
2. InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors
3. GenturaDx Announces Formation of Scientific Advisory Board
4. Michael Cusumano, MITs Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors
5. DiaTech Life Sciences Announces Medical Advisory Board
6. BioStorage Technologies Appoints New Member to Board of Directors
7. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
8. Fate Therapeutics Announces the Appointment of William H. Rastetter as Chairman of its Board of Directors and Interim CEO
9. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
10. Coalition to Save Pure Files Proxy Documents With SEC, Urges Pures Board to Set an Annual Meeting Date
11. Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 29, 2015 Research ... addition of the "Biotechnology for the Non-Biotechnologist" ... for the Non-Biotechnologist, ideal for non-Scientists and Scientists ... and potential of biotechnology. Ideal for ... theory, principles, techniques, and potential of biotechnology ...
(Date:7/6/2015)... -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today ... Clinical (Novella), to conduct the phase 3 registration ... Novella is a full-service, global clinical research organization (CRO) ... companies. The ICT-107 phase 3 trial will include approximately ... and Canada , and ...
(Date:7/3/2015)... , July 3, 2015 ... voivat hakea verkossa osoitteessa  http://www.openinnovationinscience.at ... Open Innovation in Science" -jatkokoulutusohjelmaan ... Boltzmann Gesellschaftin (LBG) tekemän, kansainvälisiä ... mukaan terveystieteiden kaksi suurinta haastetta ...
(Date:7/3/2015)... Forskare kan ansöka ... http://www.openinnovationinscience.at till det återkommande utbildningsprogrammet "Lab ... i Wien .  ... forskare och vetenskapsmän som genomfördes av Ludwig ... utmaningar bristen på incitament för att undersöka ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3
... to Exceed $8 Billion Globally by 2012VENTURA, Calif., ... a continuous, integrated and wearable remote patient monitoring ... executive officer Howard Baker will present at the ... the Marines Memorial Club and Hotel in San ...
... 7 Nuvelo, Inc.,(Nasdaq: NUVO ) ... approved,the issuance of Nuvelo Common Stock pursuant to ... between Nuvelo, ARCA biopharma and a Nuvelo,subsidiary. Nuvelo,s ... until January 23, 2009, to solicit additional proxies ...
... settled in for the,winter months and since the common ... days of school and work, now is the time ... Immunity Enhanced Beverage is designed,to do just that. , ... Products, Immunity Enhanced,Beverage is a ready-to-drink liquid supplement intended ...
Cached Biology Technology:VivoMetrics to Present at the 2009 Biotech Showcase 2VivoMetrics to Present at the 2009 Biotech Showcase 3Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 2Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 3Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 4Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 5Innovative Beverage Products Launches New Product Designed to Enhance the Body's Immune Defense 2
(Date:6/23/2015)... BEACH GARDENS, Fla. , June 23, ... multi-factor identity management and authentication solutions, today announced ... Altus strong, multi-factor authentication solution.  The enhancements ... of use of the DigitalPersona Altus platform ... biometric reader compatibility. In today,s ...
(Date:6/17/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that Xiaomi, one of the world,s largest mobile ... ® family of capacitive touchscreen solutions and ... for its latest smartphones, the Xiaomi Mi Note ... in-cell display solutions and DDICs in discrete display ...
(Date:6/16/2015)... GOTHENBURG, Sweden , June 16, 2015 ... 2015 from previously communicated that it will amount to at ... 390 MSEK. Due to the rapid increase in market growth ... from the previously communicated guidance that revenue for 2015 will ... 2015 will amount to approximately 2,200 MSEK. Due ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... origins of holiday giving and finds that our early ... arguably the foundational basis of cooperation in humans," writes ... feature of reciprocity is the contingent relationship between acts ... important because it sets the rules for who qualifies ...
... the United States could be grown inexpensively and safely ... of Central Florida molecular biologist has found. , Mice ... Daniell's laboratory through the genetic engineering of tobacco plants ... Institutes of Health researchers. The results of the NIH-funded ...
... -- a critical protein that mediates the body's defense against ... soon have greater therapeutic value as the result of a ... in St. Louis. , "Essentially, we found a way ... Michael J. Holtzman, M.D., the Selma and Herman Seldin Professor ...
Cached Biology News:Effective, safe anthrax vaccine can be grown in tobacco plants 2Effective, safe anthrax vaccine can be grown in tobacco plants 3Greasing interferon's gears may pave way to greater therapeutic benefits, fewer side effects 2
Spastin (Sp 3G11/1)...
mCD-1 10 transcription reactions...
... Maintenance 112 days/each , ... injections x5 /each , Test ... Production bleed (25 ml blood =12 ml serum) ... blood (~50 ml serum) x1 each , free ...
Mouse VCAM-1/CD106 MAb (Clone 112702)...
Biology Products: